Can a new pill outsmart depression? a trial puts KH607 to the test

NCT ID NCT07741331

Not yet recruiting Disease control Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This clinical trial is testing an investigational drug called KH607 in adults with major depressive disorder (MDD). The study compares KH607 against an existing antidepressant, vortioxetine, to see which is more effective at reducing depression symptoms. Participants will take either KH607 or vortioxetine daily for up to six weeks, and researchers will measure changes in depression severity using a standard rating scale. The trial also includes a longer-term follow-up to assess the durability of the treatment effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KH607 tablets
What this could lead to: If successful, KH607 could offer a new oral treatment option for major depressive disorder, potentially with a faster onset of action.
What could go wrong: This is a phase 3 trial, but success is not guaranteed. The drug may not prove more effective than existing antidepressants, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.